Novel 1,2,4-triazole and purine acyclic cyclopropane nucleoside analogues: synthesis, antiviral and cytostatic activity evaluations. 2011

Krešimir Benci, and Tomislav Suhina, and Leo Mandić, and Sandra Kraljević Pavelić, and Andrea Tomljenović Paravić, and Krešimir Pavelić, and Jan Balzarini, and Karlo Wittine, and Mladen Mintas
Department of Organic Chemistry, Faculty of Chemical Engineering and Technology, University of Zagreb, Zagreb, Croatia.

BACKGROUND Several published studies indicate that the acyclic guanine nucleoside analogues possessing bis(1,2-hydroxymethyl) substituted cyclopropane rings mimicking the sugar moiety are potent inhibitors of replication of several herpes viruses. METHODS Established synthetic methods and antiviral and cytostatic activity assays were used for the evaluation of new 1,2,4-triazole and purine acyclic nucleoside analogues. RESULTS The synthesis of new types of acyclic nucleoside analogues which incorporate 1,2,4-triazole or purine moiety bound via flexible methylenic spacer to the bis(1,2-hydroxymethyl) cyclopropane ring. None of the new compounds showed pronounced antiviral activities at subtoxic concentrations on a broad panel of DNA and RNA viruses. Evaluation of their affinity for herpes simplex type 1 (HSV-1) and varicella-zoster virus-encoded thymidine kinases (VZV TK) also showed that none of the compounds was able to significantly inhibit 1 μM deoxythymidine phosphorylation by HSV-1 and VZV TK at 500 μM concentrations. The in vitro cytostatic activity evaluation results indicated a weak antiproliferative activity for all tested compounds. Only 6-pyrrolylpurine derivative bearing a carboxylic group substituted cyclopropane ring produced a rather slight inhibitory effect at higher micromolar concentrations on a breast carcinoma cell line (MCF-7) and no cytotoxic effect on human normal fibroblasts (WI 38). CONCLUSIONS The lack of antiherpetic activity may be due to poor, if any, recognition of the compounds by virus-induced nucleoside kinases as an alternative substrate to become metabolically activated.

UI MeSH Term Description Entries
D009682 Magnetic Resonance Spectroscopy Spectroscopic method of measuring the magnetic moment of elementary particles such as atomic nuclei, protons or electrons. It is employed in clinical applications such as NMR Tomography (MAGNETIC RESONANCE IMAGING). In Vivo NMR Spectroscopy,MR Spectroscopy,Magnetic Resonance,NMR Spectroscopy,NMR Spectroscopy, In Vivo,Nuclear Magnetic Resonance,Spectroscopy, Magnetic Resonance,Spectroscopy, NMR,Spectroscopy, Nuclear Magnetic Resonance,Magnetic Resonance Spectroscopies,Magnetic Resonance, Nuclear,NMR Spectroscopies,Resonance Spectroscopy, Magnetic,Resonance, Magnetic,Resonance, Nuclear Magnetic,Spectroscopies, NMR,Spectroscopy, MR
D010766 Phosphorylation The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. Phosphorylations
D011684 Purine Nucleosides Purines with a RIBOSE attached that can be phosphorylated to PURINE NUCLEOTIDES. Purine Nucleoside,Nucleoside, Purine,Nucleosides, Purine
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D004267 DNA Viruses Viruses whose nucleic acid is DNA. DNA Virus,Virus, DNA,Viruses, DNA
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D005347 Fibroblasts Connective tissue cells which secrete an extracellular matrix rich in collagen and other macromolecules. Fibroblast
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Krešimir Benci, and Tomislav Suhina, and Leo Mandić, and Sandra Kraljević Pavelić, and Andrea Tomljenović Paravić, and Krešimir Pavelić, and Jan Balzarini, and Karlo Wittine, and Mladen Mintas
January 2008, Nucleic acids symposium series (2004),
Krešimir Benci, and Tomislav Suhina, and Leo Mandić, and Sandra Kraljević Pavelić, and Andrea Tomljenović Paravić, and Krešimir Pavelić, and Jan Balzarini, and Karlo Wittine, and Mladen Mintas
March 2019, ACS combinatorial science,
Krešimir Benci, and Tomislav Suhina, and Leo Mandić, and Sandra Kraljević Pavelić, and Andrea Tomljenović Paravić, and Krešimir Pavelić, and Jan Balzarini, and Karlo Wittine, and Mladen Mintas
December 2006, Bioorganic & medicinal chemistry,
Krešimir Benci, and Tomislav Suhina, and Leo Mandić, and Sandra Kraljević Pavelić, and Andrea Tomljenović Paravić, and Krešimir Pavelić, and Jan Balzarini, and Karlo Wittine, and Mladen Mintas
January 1998, Advances in experimental medicine and biology,
Krešimir Benci, and Tomislav Suhina, and Leo Mandić, and Sandra Kraljević Pavelić, and Andrea Tomljenović Paravić, and Krešimir Pavelić, and Jan Balzarini, and Karlo Wittine, and Mladen Mintas
July 2010, Nucleosides, nucleotides & nucleic acids,
Krešimir Benci, and Tomislav Suhina, and Leo Mandić, and Sandra Kraljević Pavelić, and Andrea Tomljenović Paravić, and Krešimir Pavelić, and Jan Balzarini, and Karlo Wittine, and Mladen Mintas
February 2009, Nucleosides, nucleotides & nucleic acids,
Krešimir Benci, and Tomislav Suhina, and Leo Mandić, and Sandra Kraljević Pavelić, and Andrea Tomljenović Paravić, and Krešimir Pavelić, and Jan Balzarini, and Karlo Wittine, and Mladen Mintas
May 2008, Bioorganic & medicinal chemistry,
Krešimir Benci, and Tomislav Suhina, and Leo Mandić, and Sandra Kraljević Pavelić, and Andrea Tomljenović Paravić, and Krešimir Pavelić, and Jan Balzarini, and Karlo Wittine, and Mladen Mintas
April 1990, Journal of medicinal chemistry,
Krešimir Benci, and Tomislav Suhina, and Leo Mandić, and Sandra Kraljević Pavelić, and Andrea Tomljenović Paravić, and Krešimir Pavelić, and Jan Balzarini, and Karlo Wittine, and Mladen Mintas
June 2008, Chemical biology & drug design,
Krešimir Benci, and Tomislav Suhina, and Leo Mandić, and Sandra Kraljević Pavelić, and Andrea Tomljenović Paravić, and Krešimir Pavelić, and Jan Balzarini, and Karlo Wittine, and Mladen Mintas
November 2001, Journal of medicinal chemistry,
Copied contents to your clipboard!